Orakl Oncology is dedicated to advancing drug discovery in oncology through innovative technologies that focus on personalized medicine. The company utilizes advanced tumor models that closely replicate real-life drug responses, leveraging over 28 years of combined research and development expertise. These models are enhanced by integrating deep patient data, which includes detailed clinical and omics information, allowing for a comprehensive interpretation of biological results. This approach ensures that the insights gained from their research are contextually relevant and applicable to real-world patient scenarios.

A key component of Orakl Oncology's technology is its AI-powered analysis, which enables the mining of multi-modal experimental data in conjunction with deep patient data. This sophisticated analysis provides unique insights that can drive the development of more effective cancer treatments. The team at Orakl Oncology comprises experts in various fields, including organoid technology, computational biology, and data science, all of whom contribute to the company's mission of improving patient care through innovative scientific solutions.

France

Orakl Oncology leverages a unique collection of patient tumor avatars that combines biology and clinical data to fuel the therapeutic arsenal to fight cancer. With our platform we partner with oncology players to identify relevant targets and deliver new drugs, faster.

Orakl Oncology

Company Details